NTLA - Intellia Therapeutics

-

$undefined

N/A

(N/A)

Intellia Therapeutics NasdaqGM:NTLA Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Location: 40 Erie Street, Cambridge, MA, 02139, United States | Website: https://www.intelliatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

387.2M

Cash

503.7M

Avg Qtr Burn

-94.29M

Short % of Float

31.18%

Insider Ownership

4.96%

Institutional Own.

96.90%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
nexiguran ziclumeran (nex-z) (NTLA-2001) Details
ATTR amyloidosis with polyneuropathy (ATTRv-PN)

Phase 3

Data readout

NTLA-2002 (KLKB1 Inhibitor) Details
Hereditary angioedema , Rare diseases, Rare genetic disease

Phase 1/2

Data readout

NTLA-3001 Details
Alpha-1 Antitrypsin Deficiency, Lung disease

Phase 1/2

Update

nexiguran ziclumeran (nex-z) (NTLA-2001) Details
Transthyretin Amyloid Cardiomyopathy

Phase 1

Update

NTLA-5001 Details
Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued